WEKO3
アイテム
Coronavirus disease 2019 in a patient with pulmonary fibrosis and emphysema: An autopsy report
http://hdl.handle.net/10458/0002000415
http://hdl.handle.net/10458/00020004158733cfba-4280-48db-88d9-40459269b0ee
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
article (4.6 MB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2023-12-26 | |||||||||||
| タイトル | ||||||||||||
| タイトル | Coronavirus disease 2019 in a patient with pulmonary fibrosis and emphysema: An autopsy report | |||||||||||
| 言語 | en | |||||||||||
| 言語 | ||||||||||||
| 言語 | eng | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| キーワード | COVID-19 | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| キーワード | SARS-CoV-2 | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| キーワード | AutopsyInterstitial lung disease | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| キーワード | Acute respiratory distress syndrome | |||||||||||
| 資源タイプ | ||||||||||||
| 資源タイプ | journal article | |||||||||||
| 著者 |
工藤, 理紗
× 工藤, 理紗× 川口, 剛× 木村, 賢俊× 力武, 雄幹× 岩尾, 千紘× 力武, 真央× 岩尾, 浩昭× 相澤, 彩子× 仮屋, 裕美× 松田, 基弘× 宮内, 俊一
WEKO
9652
× 高城, 一郎× 佐藤, 勇一郎× 浅田, 祐士郎× 宮崎, 泰可× 梅北, 邦彦 |
|||||||||||
| 抄録 | ||||||||||||
| 内容記述タイプ | Abstract | |||||||||||
| 内容記述 | Various diseases (e.g., hypertension and diabetes) are risk factors for the exacerbation of coronavirus 2019 (COVID-19). Patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) tend to develop severe COVID-19. Patients with severe COVID-19 present with acute respiratory distress syndrome (ARDS), and many COVID-19-related ARDS survivors eventually develop fibrosis. However, the appropriate management of patients with COVID-19 and ILD and post-COVID-19 ILD remains unclear. Thus, a better understanding of the pathology that exacerbates COVID-19 in patients with ILD is needed. We report the autopsy results of a patient with COVID-19 and combined pulmonary fibrosis and emphysema, whose lung organization and fibrosis progressed after the acute phase of infection. Histopathological findings suggest that fatal pulmonary fibrosis persists after the negative conversion of SARS-CoV-2. Elucidating the cause of death by autopsy may help determine therapeutic strategies in patients with COVID-19 and ILD. Vaccination and early administration of anti-inflammatory drugs or antifibrotic agents may be crucial for preventing disease progression and fatal lung fibrosis. This report aims to clarify the histopathological features of COVID-19 in patients with ILD via autopsy and discuss treatment strategies. | |||||||||||
| 言語 | en | |||||||||||
| 内容記述 | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | Citation: Kudo R, Kawaguchi T, Kimura M, Rikitake Y, Iwao C, Rikitake M, Iwao K, Aizawa A, Kariya Y, Matsuda M, Miyauchi S, Takajo I, Sato Y, Asada Y, Miyazaki T, Umekita K. Coronavirus disease 2019 in a patient with pulmonary fibrosis and emphysema: An autopsy report. Heliyon. 2023 Nov 10;9(11):e22221. doi: 10.1016/j.heliyon.2023.e22221. PMID: 38045178; PMCID: PMC10692797. |
|||||||||||
| 言語 | en | |||||||||||
| 書誌情報 |
en : Heliyon 巻 9, 号 11, p. e22221 |
|||||||||||
| 出版者 | ||||||||||||
| 出版者 | Elsevier | |||||||||||
| 言語 | en | |||||||||||
| ISSN | ||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||
| 収録物識別子 | 24058440 | |||||||||||
| DOI | ||||||||||||
| 関連タイプ | isVersionOf | |||||||||||
| 識別子タイプ | DOI | |||||||||||
| 関連識別子 | https://doi.org/10.1016/j.heliyon.2023.e22221 | |||||||||||
| 権利 | ||||||||||||
| 言語 | en | |||||||||||
| 権利情報 | © 2023 The Authors. Published by Elsevier Ltd. | |||||||||||
| 著者版フラグ | ||||||||||||
| 出版タイプ | VoR | |||||||||||
